falsefalse

Evolving Treatment Strategies in High-Risk Neuroblastoma - Episode 7

Available Treatment Options for Recurrent/Relapsed High-Risk Neuroblastoma (R/R HRNB)

,

Key opinion leaders address the treatment of recurrent or relapsed high-risk neuroblastoma, emphasizing the efficacy of antibody therapies naxitamab and dinutuximab, which target neuroblastoma cells, and the significance of post-induction therapy to enhance patient outcomes before transplantation.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: An Overview of Neuroblastoma
    EP. 2: Approaches to Diagnosing Neuroblastoma
    EP. 3: Role of CURIE Scores in the Treatment and Management of Neuroblastoma
    EP. 4: Current Treatment Paradigm for Newly Diagnosed Neuroblastoma
    EP. 5: Differentiating Refractory and Relapsed Neuroblastoma
    EP. 6: Updated Data From the LEAHRN Study in High-Risk Neuroblastoma
    Now Viewing
    EP. 7: Available Treatment Options for Recurrent/Relapsed High-Risk Neuroblastoma (R/R HRNB)
    EP. 8: Anti-GD2 Monoclonal Antibodies in Patients With R/R HRNB: Pivotal Clinical Trials
    EP. 9: Strategies for Adverse Effect Management and Treatment Optimization With Anti-GD2 Monoclonal Antibodies in R/R
    EP. 10: Future Perspectives in the Treatment of Neuroblastoma

    Related Content:

    Evolving Treatment Strategies in High-Risk NeuroblastomaOncLive News Network®
    Treatment Trends and Ongoing Research in Pediatric Acute Leukemia
    Factors to Consider in Pediatric Acute Leukemia Management
    Breaking Down Treatment Expectations With Revumenib in Pediatric KMT2A+ R/R Acute Leukemia
    x